Agata Michalak
8 Jaczewskiego Str
Lublin, LU 20090, Poland
Lublin, LU 20090, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Multicentre retrospective real-world evidence study evaluating the effectiveness and safety of mirikizumab in patients with moderately to severely active ulcerative colitis.
Journal: Przeglad gastroenterologiczny
Published: March 30, 2026
Clinical Response and Improvement of the Quality of Life, Fatigue, Mood, and Sleep Disturbances During Vedolizumab Induction Therapy in Polish Patients With Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
Journal: Canadian journal of gastroenterology & hepatology
Published: May 19, 2025
miRNAs and Hematological Markers in Non-Alcoholic Fatty Liver Disease-A New Diagnostic Path?
Journal: Biomedicines
Published: January 02, 2025
Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment.
Journal: International journal of molecular sciences
Published: March 18, 2024
Effectiveness and safety outcomes after long-term (54 weeks) vedolizumab therapy for Crohn's disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II).
Journal: Therapeutic advances in gastroenterology
Published: January 31, 2024
COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?
Journal: International journal of molecular sciences
Published: January 01, 2024
Impact of Obesity on the Course of Management of Inflammatory Bowel Disease-A Review.
Journal: Nutrients
Published: August 03, 2022
Red blood cell distribution width derivatives in alcohol-related liver cirrhosis and metabolic-associated fatty liver disease.
Journal: World journal of gastroenterology
Published: July 04, 2022
The Usefulness of Extended Inflammation Parameters and Systemic Inflammatory Response Markers in the Diagnostics of Autoimmune Hepatitis.
Journal: Cells
Published: July 03, 2022
Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study.
Journal: Therapeutic advances in gastroenterology
Published: May 06, 2022
Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study.
Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University
Published: April 22, 2022
Last Updated: 09/26/2026